By: Emily MacHale
Tustin, CA – Executives of the Integrium team will be in Boston during the Alliance for Regenerative Medicine 5th Annual Cell & Gene Investor Day on April 27th, 2017. On this one day filled with opportunity for investors to collaborate with advanced therapeutic biotechs, Integrium seeks to meet and gain insight on how they can be of help to numerous life science experts.
Hearing from industry leaders helps Integrium with effectively positioning themselves in the biotech marketplace regarding investment and financing opportunities. Meanwhile, Integrium can understand the needs of biotechs and what they require during their search for an investor. With over 350 attendees and more than 175 of them active investors and analysts, Integrium is successfully able to meet with clinical experts and develop one-on-one relationships.
Integrium helps micro-cap, small-cap, and small private biotechs attain clinical data so they can raise their next round of capital. Integrium typically invests in two to four private biotechs each year and have the ability and goal to take on 3 more investments in 2017. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.
Check out our new website!
To learn more about Integrium, contact:
Associate Director of Marketing & Research